Clinical Guideline InSights
The 2026 Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events Scientific Statement and the 2026 Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease Scientific Statement * Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events/Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease * American College of Cardiology * June 30, 2026 * Guideline Summary: https://www.guidelinecentral.com/guideline/5230408/ [https://www.guidelinecentral.com/guideline/5230408/] / https://www.guidelinecentral.com/guideline/5230407/ [https://www.guidelinecentral.com/guideline/5230407/] * Full-Text: https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033 [https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033] / https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2 [https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2]
57 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Clinical Guideline InSights community!